Prevalence and determinants of opioid use disorder among long-term opiate users in Golestan Cohort Study.
Cohort studies
Iran
Opiate
Opioid use disorder
Opium
Substance-related disorders
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
21 Dec 2023
21 Dec 2023
Historique:
received:
25
07
2023
accepted:
03
12
2023
medline:
22
12
2023
pubmed:
22
12
2023
entrez:
22
12
2023
Statut:
epublish
Résumé
Number of opiate users worldwide has doubled over the past decade, but not all of them are diagnosed with opioid use disorder. We aimed to identify the prevalence and risk factors for OUD after ten years of follow-up. Among 8,500 chronic opiate users at Golestan Cohort Study baseline (2004-2008), we recalled a random sample of 451 subjects in 2017. We used three questionnaires: a questionnaire about current opiate use including type and route of use, the drug use disorder section of the Composite International Diagnostic Interview lifetime version, and the validated Kessler10 questionnaire. We defined opioid use disorder and its severity based on the DSM-5 criteria and used a cutoff of 12 on Kessler10 questionnaire to define psychological distress. Mean age was 61.2 ± 6.6 years (84.7% males) and 58% were diagnosed with opioid use disorder. Starting opiate use at an early age and living in underprivileged conditions were risk factors of opioid use disorder. Individuals with opioid use disorder were twice likely to have psychological distress (OR = 2.25; 95%CI: 1.44-3.52) than the users without it. In multivariate regression, former and current opiate dose and oral use of opiates were independently associated with opioid use disorder. Each ten gram per week increase in opiate dose during the study period almost tripled the odds of opioid use disorder (OR = 3.18; 95%CI: 1.79-5.63). Chronic opiate use led to clinical opioid use disorder in more than half of the users, and this disorder was associated with psychological distress, increasing its physical and mental burden in high-risk groups.
Sections du résumé
BACKGROUND
BACKGROUND
Number of opiate users worldwide has doubled over the past decade, but not all of them are diagnosed with opioid use disorder. We aimed to identify the prevalence and risk factors for OUD after ten years of follow-up.
METHODS
METHODS
Among 8,500 chronic opiate users at Golestan Cohort Study baseline (2004-2008), we recalled a random sample of 451 subjects in 2017. We used three questionnaires: a questionnaire about current opiate use including type and route of use, the drug use disorder section of the Composite International Diagnostic Interview lifetime version, and the validated Kessler10 questionnaire. We defined opioid use disorder and its severity based on the DSM-5 criteria and used a cutoff of 12 on Kessler10 questionnaire to define psychological distress.
RESULTS
RESULTS
Mean age was 61.2 ± 6.6 years (84.7% males) and 58% were diagnosed with opioid use disorder. Starting opiate use at an early age and living in underprivileged conditions were risk factors of opioid use disorder. Individuals with opioid use disorder were twice likely to have psychological distress (OR = 2.25; 95%CI: 1.44-3.52) than the users without it. In multivariate regression, former and current opiate dose and oral use of opiates were independently associated with opioid use disorder. Each ten gram per week increase in opiate dose during the study period almost tripled the odds of opioid use disorder (OR = 3.18; 95%CI: 1.79-5.63).
CONCLUSIONS
CONCLUSIONS
Chronic opiate use led to clinical opioid use disorder in more than half of the users, and this disorder was associated with psychological distress, increasing its physical and mental burden in high-risk groups.
Identifiants
pubmed: 38129791
doi: 10.1186/s12888-023-05436-x
pii: 10.1186/s12888-023-05436-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
958Informations de copyright
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
World Drug. Report 2021 (United Nations publication, Sales No. E.21.XI.8).
Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet Lond Engl. 2019;394(10208):1560–79.
doi: 10.1016/S0140-6736(19)32229-9
GBD 2016 Alcohol and Drug Use Collaborators. The global burden of Disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the global burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987–1012.
doi: 10.1016/S2215-0366(18)30337-7
Liu YS, Kiyang L, Hayward J, Zhang Y, Metes D, Wang M et al. Individualized prospective prediction of opioid Use Disorder. Can J Psychiatry Rev Can Psychiatr. 2022;7067437221114094.
Cragg A, Hau JP, Woo SA, Kitchen SA, Liu C, Doyle-Waters MM, et al. Risk factors for misuse of prescribed opioids: a systematic review and Meta-analysis. Ann Emerg Med. 2019;74(5):634–46.
pubmed: 31229388
doi: 10.1016/j.annemergmed.2019.04.019
Webster LR. Risk factors for opioid-use disorder and Overdose. Anesth Analg. 2017;125(5):1741–8.
pubmed: 29049118
doi: 10.1213/ANE.0000000000002496
Kessler RC, Barker PR, Colpe LJ, Epstein JF, Gfroerer JC, Hiripi E, et al. Screening for serious mental Illness in the general population. Arch Gen Psychiatry. 2003;60(2):184–9.
pubmed: 12578436
doi: 10.1001/archpsyc.60.2.184
Hajebi A, Motevalian A, Amin-Esmaeili M, Rahimi-Movaghar A, Sharifi V, Hoseini L, et al. Adaptation and validation of short scales for assessment of psychological distress in Iran: the persian K10 and K6. Int J Methods Psychiatr Res. 2018;27(3):e1726.
pubmed: 29888523
pmcid: 6877187
doi: 10.1002/mpr.1726
IARC Monographs Vol 126 group. Carcinogenicity of opium consumption. Lancet Oncol. 2020;21(11):1407–8.
doi: 10.1016/S1470-2045(20)30611-2
Mansouri M, Naghshi S, Parsaeian M, Sepanlou G, Poustchi S, Momayez Sanat H. Opium Use and Cancer Risk: a comprehensive systematic review and Meta-analysis of Observational studies. Int J Clin Pract. 2022;2022:5397449.
pubmed: 35685572
pmcid: 9159125
doi: 10.1155/2022/5397449
Nakhaee S, Ghasemi S, Karimzadeh K, Zamani N, Alinejad-Mofrad S, Mehrpour O. The effects of opium on the cardiovascular system: a review of side effects, uses, and potential mechanisms. Subst Abuse Treat Prev Policy. 2020;15(1):30.
pubmed: 32303254
pmcid: 7164148
doi: 10.1186/s13011-020-00272-8
Khademi H, Malekzadeh R, Pourshams A, Jafari E, Salahi R, Semnani S, et al. Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran. BMJ. 2012;344:e2502.
pubmed: 22511302
pmcid: 3328545
doi: 10.1136/bmj.e2502
United Nations Office on Drugs and Crime. World drug report 2020. Vienna: United Nations., 2020. https://wdr.unodc.org/wdr2020/field/WDR20_Booklet_3.pdf (accessed Oct 6, 2020).
Rahimi-Movaghar A, Gholami J, Amato L, Hoseinie L, Yousefi-Nooraie R, Amin-Esmaeili M. Pharmacological therapies for management of opium withdrawal. Cochrane Database Syst Rev. 2018;6:CD007522.
pubmed: 29929212
Raeis Dana F. The Drug Market in Iran. Soc Welf Q. 2003;3(9):243–62.
Noorbala AA, Saljoughian A, Bagheri Yazdi SA, Faghihzadeh E, Farahzadi MH, Kamali K, et al. Evaluation of drug and alcohol abuse in people aged 15 years and older in Iran. Iran J Public Health. 2020;49(10):1940–6.
pubmed: 33346232
pmcid: 7719666
Amin-Esmaeili M, Rahimi-Movaghar A, Sharifi V, Hajebi A, Radgoodarzi R, Mojtabai R, et al. Epidemiology of illicit Drug Use Disorders in Iran: prevalence, correlates, comorbidity and service utilization results from the Iranian Mental Health Survey. Addict Abingdon Engl. 2016;111(10):1836–47.
doi: 10.1111/add.13453
Amin-Esmaeili M, Rahimi-Movaghar A, Sharifi V, Hajebi A, Radgoodarzi R, Mojtabai R, et al. Epidemiology of illicit Drug Use Disorders in Iran: prevalence, correlates, comorbidity and service utilization results from the Iranian Mental Health Survey. Addiction. 2016;111(10):1836–47.
pubmed: 27177849
doi: 10.1111/add.13453
Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. The Lancet. 2019;394(10208):1560–79.
doi: 10.1016/S0140-6736(19)32229-9
Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, Sadjadi AR, et al. Cohort Profile: the Golestan Cohort Study–a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol. 2010;39(1):52–9.
pubmed: 19332502
doi: 10.1093/ije/dyp161
Abnet CC, Saadatian-Elahi M, Pourshams A, Boffetta P, Feizzadeh A, Brennan P, et al. Reliability and validity of opiate use self-report in a population at high risk for Esophageal cancer in Golestan, Iran. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2004;13(6):1068–70.
doi: 10.1158/1055-9965.1068.13.6
Arabgol F, Alaghband Rad J, Sharifi V, Hakim-shoushtari M, Shabani A, Davari-Ashtiani R et al. Reliability of a persian translation of the Composite International Diagnostic interview (CIDI), section for substance use disorders: in a multi-center study in Iran. Adv Cogn Sci. 2005;7.
Wittchen HU. Reliability and validity studies of the WHO–Composite International Diagnostic interview (CIDI): a critical review. J Psychiatr Res. 1994;28(1):57–84.
pubmed: 8064641
doi: 10.1016/0022-3956(94)90036-1
Hajebi A, Motevalian A, Amin-Esmaeili M, Rahimi‐Movaghar A, Sharifi V, Hoseini L et al. Adaptation and validation of short scales for assessment of psychological distress in Iran: The Persian K10 and K6. Int J Methods Psychiatr Res [Internet]. 2018 Sep [cited 2023 Jan 11];27(3). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877187/ .
Kessler RC, Green JG, Gruber MJ, Sampson NA, Bromet E, Cuitan M, et al. Screening for serious mental Illness in the general population with the K6 screening scale: results from the WHO World Mental Health (WMH) survey initiative. Int J Methods Psychiatr Res. 2010;19(Suppl 1):4–22.
pubmed: 20527002
pmcid: 3659799
doi: 10.1002/mpr.310
La P. Serious psychological distress, as measured by the K6, and mortality. Ann Epidemiol [Internet]. 2009 Mar [cited 2022 Jun 14];19(3). Available from: https://pubmed.ncbi.nlm.nih.gov/19217003/ .
Olfson M, Wang S, Wall M, Marcus SC, Blanco C. Trends in Serious Psychological Distress and Outpatient Mental Health Care of US adults. JAMA Psychiatry. 2019;76(2):152–61.
pubmed: 30484838
doi: 10.1001/jamapsychiatry.2018.3550
Sampasa-Kanyinga H, Zamorski MA, Colman I. The psychometric properties of the 10-item Kessler Psychological Distress Scale (K10) in Canadian military personnel. PLoS ONE. 2018;13(4):e0196562.
pubmed: 29698459
pmcid: 5919406
doi: 10.1371/journal.pone.0196562
Mohebbi E, Kamangar F, Rahimi-Movaghar A, Haghdoost AA, Etemadi A, Amirzadeh S, et al. An Exploratory Study of Units of Reporting Opium Usein Iran: implications for epidemiologic studies. Arch Iran Med. 2019;22(10):541–5.
pubmed: 31679354
Islami F, Kamangar F, Nasrollahzadeh D, Aghcheli K, Sotoudeh M, Abedi-Ardekani B, et al. Socio-economic status and oesophageal cancer: results from a population-based case–control study in a high-risk area. Int J Epidemiol. 2009;38(4):978–88.
pubmed: 19416955
pmcid: 2720396
doi: 10.1093/ije/dyp195
(2019). Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Substance Abuse and Mental Health Services Administration, Series H-. 54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/ .
Kalkman GA, Kramers C, van Dongen RT, van den Brink W, Schellekens A. Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study. Lancet Public Health. 2019;4(10):e498–505.
pubmed: 31444001
doi: 10.1016/S2468-2667(19)30128-8
W H, Dp EB, E FGD. F, T H, Is Europe also facing an opioid crisis?-A survey of European Pain Federation chapters. Eur J Pain Lond Engl [Internet]. 2021 Sep [cited 2022 Nov 2];25(8). Available from: https://pubmed.ncbi.nlm.nih.gov/33960569/ .
Rahimi-Movaghar A, Amin-Esmaeili M, Sharifi V, Hajebi A, Radgoodarzi R, Hefazi M, et al. Iranian mental health survey: design and field proced. Iran J Psychiatry. 2014;9(2):96–109.
pubmed: 25632287
pmcid: 4300472
Najafipour H, Masoumi M, Amirzadeh R, Rostamzadeh F, Foad R, Shadkam Farrokhi M. Trends in the prevalence and Incidence of Opium Abuse and its association with coronary artery risk factors in Adult Population in Iran: findings from Kerman coronary artery Disease risk factors study. Iran J Med Sci. 2022;47(4):328–37.
pubmed: 35919081
pmcid: 9339109
Najafipour H, Banivaheb G, Sabahi A, Naderi N, Nasirian M, Mirzazadeh A. Prevalence of anxiety and depression symptoms and their relationship with other coronary artery Disease risk factors: a population-based study on 5900 residents in Southeast Iran. Asian J Psychiatry. 2016;20:55–60.
doi: 10.1016/j.ajp.2016.01.004
Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019;197:78–82.
pubmed: 30784952
doi: 10.1016/j.drugalcdep.2018.12.030
Lai HMX, Cleary M, Sitharthan T, Hunt GE. Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014: a systematic review and meta-analysis. Drug Alcohol Depend. 2015;154:1–13.
pubmed: 26072219
doi: 10.1016/j.drugalcdep.2015.05.031
Jané-Llopis E, Matytsina I. Mental health and alcohol, Drugs and Tobacco: a review of the comorbidity between mental disorders and the use of alcohol, Tobacco and illicit Drugs. Drug Alcohol Rev. 2006;25(6):515–36.
pubmed: 17132571
doi: 10.1080/09595230600944461
Kessler RC, Ustün TB. The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic interview (CIDI). Int J Methods Psychiatr Res. 2004;13(2):93–121.
pubmed: 15297906
doi: 10.1002/mpr.168
Gyawali B, Choulagai BP, Paneru DP, Ahmad M, Leppin A, Kallestrup P. Prevalence and correlates of psychological distress symptoms among patients with substance use disorders in drug rehabilitation centers in urban Nepal: a cross-sectional study. BMC Psychiatry. 2016;16(1):314.
pubmed: 27609330
pmcid: 5015326
doi: 10.1186/s12888-016-1003-6
Chan K, Moller M, Marsack-Topolewski C, Winston P, Jennings R, Prifti A. Age differences in non-medical prescription opioid use and psychological distress. Subst Use Misuse. 2020;55(11):1808–16.
pubmed: 32441182
doi: 10.1080/10826084.2020.1765808
Danielsson AK, Lundin A, Allebeck P, Agardh E. Cannabis use and psychological distress: an 8-year prospective population-based study among Swedish men and women. Addict Behav. 2016;59:18–23.
pubmed: 27010850
doi: 10.1016/j.addbeh.2016.03.005
Nalini M, Shakeri R, Poustchi H, Pourshams A, Etemadi A, Islami F, et al. Long-term opiate use and risk of cardiovascular mortality: results from the Golestan Cohort Study. Eur J Prev Cardiol. 2021;28(1):98–106.
pubmed: 33624066
doi: 10.1093/eurjpc/zwaa006
Rahmati A, Shakeri R, Khademi H, Poutschi H, Pourshams A, Etemadi A, et al. Mortality from Respiratory Diseases associated with opium use: a population-based cohort study. Thorax. 2017;72(11):1028–34.
pubmed: 27885167
doi: 10.1136/thoraxjnl-2015-208251
Malekzadeh MM, Khademi H, Pourshams A, Etemadi A, Poustchi H, Bagheri M, et al. Opium Use and Risk of Mortality from Digestive Diseases: a prospective cohort study. Off J Am Coll Gastroenterol ACG. 2013;108(11):1757–65.
doi: 10.1038/ajg.2013.336
Etemadi A, Hariri S, Hassanian-moghaddam H, Poustchi H, Roshandel G, Shayanrad A, et al. Lead Poisoning among asymptomatic individuals with a long-term history of opiate use in Golestan Cohort Study. Int J Drug Policy. 2022;104:103695.
pubmed: 35472727
pmcid: 9133202
doi: 10.1016/j.drugpo.2022.103695
Schepis TS, Hakes JK. Age of initiation, psychopathology, and other substance use are associated with time to use disorder diagnosis in persons using opioids nonmedically. Subst Abuse. 2017;38(4):407–13.
doi: 10.1080/08897077.2017.1356791
Wall M, Cheslack-Postava K, Hu MC, Feng T, Griesler P, Kandel DB. Nonmedical prescription opioids and pathways of drug involvement in the US: generational differences. Drug Alcohol Depend. 2018;182:103–11.
pubmed: 29220668
doi: 10.1016/j.drugalcdep.2017.10.013
Han B, Compton WM, Jones CM, Cai R. Nonmedical prescription opioid Use and Use disorders among adults aged 18 through 64 years in the United States, 2003–2013. JAMA. 2015;314(14):1468–78.
pubmed: 26461997
doi: 10.1001/jama.2015.11859
Alvanzo AAH, Storr CL, La Flair L, Green KM, Wagner FA, Crum RM. Race/ethnicity and sex differences in progression from drinking initiation to the development of alcohol dependence. Drug Alcohol Depend. 2011;118(2–3):375–82.
pubmed: 21652154
pmcid: 3190032
doi: 10.1016/j.drugalcdep.2011.04.024
World Drug Report. 2018 (United Nations publication, Sales No. E.18.XI.9).